Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease
Summary
Government support, alongside private investments, funds first wave of pivotal Phase 3 trial of sonlicromanol for m.3243A>G Primary Mitochondrial Disease (PMD)NIJMEGEN, Netherlands, May 6, 2025 /PRNewswire/ -- Khondrion, a clinical-stage biopharmaceutical company pioneering therapies for primary mitochondrial disease (PMD), today announced it has been awarded an Innovation Credit of up to 5 million from the Netherlands Enterprise Agency, a government agency that supports entrepreneurs.This vital government funding, matched by a significant investment from Khondrions committed private backers, will fund Wave 1 of the companys pivotal Phase 3 clinical trial of sonlicromanol. The Phase 3 trial is expected to launch in H2-2025, marking a crucial milestone in Khondrions mission to deliver the first approved treatment for these devastating, multisystem disorders.Primary mitochondrial diseases are a group of rare, progressive, and life-altering disorders that disrupt the bodys ability to generate energy. This leads to a wide range of severe symptoms across multiple organ systems, including the brain, muscles, and digestive tract. "With sonlicromanol, we are advancing a potentially transformative therapy designed not only to alleviate symptoms but also to modify the course of this devastating disease, offering new hope to patients and families who have long been waiting for effective solutions. Adult patients participating in our extensive Phase 2 programme have reported continued and progressive improvements on key symptoms (see Smeitink et al., Brain 2025; https://doi.org/10.1093/brain/awae277).